💊 医薬品 A-Z 🧬 標的 🛠 ツール 📚 ガイド
全医薬品 薬物分類 治療領域 副作用
ガイド 用語集 年表
比較 薬物の体内の旅 薬物ファミリー
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Citalopram

CHEMBL549 Phase 4 承認済み Small molecule
Half-Life
35 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
324.4 g/mol
LogP
3.2
Phase
4

A selective serotonin reuptake inhibitor (SSRI) that increases serotonin availability in synapses by blocking the serotonin transporter, used to treat major depressive disorder, panic disorder, and obsessive-compulsive disorder. It has a relatively favorable side effect and drug interaction profile compared to older antidepressants. QT prolongation is a dose-dependent concern, and doses above 40 mg daily are not recommended.

分子量

324.3920 g/mol

LogP

3.20

TPSA

36.30 Ų

リピンスキーの五則

適合

治療領域

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Cardiovascular Disease Respiratory Disease Pain Management Non-Small Cell Lung Cancer Rheumatoid Arthritis Asthma Chronic Obstructive Pulmonary Disease Alzheimer's Disease Parkinson's Disease Epilepsy Schizophrenia Bipolar Disorder Generalized Anxiety Disorder Insomnia Infectious Disease Gastroesophageal Reflux Disease Inflammatory Bowel Disease Psoriasis Multiple Sclerosis Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Stroke Obesity Type 2 Diabetes Hypertension Major Depressive Disorder Breast Cancer Chronic Pain HIV/AIDS Hepatitis C Heart Failure Prostate Cancer Colorectal Cancer

薬物分類

N — N - Nervous System

作用機序

Selective serotonin reuptake inhibitor (SSRI); racemic mixture with escitalopram as active S-enantiomer.

Pharmacokinetics (PK)

Half-Life 35 hours

Pharmacodynamics (PD)

機序

Selective serotonin reuptake inhibitor (SSRI); racemic mixture with escitalopram as active S-enantiomer.

2D構造

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CN(C)CCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21

                

                

                
                

                    
InChI

                    
InChI=1S/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3

                

                

                

                    
                    

                        
Molecular Formula

                        
C20H21FN2O

                    

                    
                    

                        
HBD / HBA

                        
- / 4

                    

                    
                    

                        
回転可能結合数

                        
5

                    

                    
                    
                    

                        
重原子数

                        
24

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
よくある質問

                

                    
                    

                        
                        

                            
A selective serotonin reuptake inhibitor (SSRI) that increases serotonin availability in synapses by blocking the serotonin transporter, used to treat major depressive disorder, panic disorder, and obsessive-compulsive disorder. It has a relatively favorable side effect and drug interaction profile compared to older antidepressants. QT prolongation is a dose-dependent concern, and doses above 40 mg daily are not recommended.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Selective serotonin reuptake inhibitor (SSRI); racemic mixture with escitalopram as active S-enantiomer.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Citalopram: Half-life: 35 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Citalopram is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Acetaminophen
                            Small molecule
                        
                        
                        
                            Aspirin
                            Small molecule
                        
                        
                        
                            Sertraline
                            Small molecule
                        
                        
                        
                            Escitalopram
                            Small molecule
                        
                        
                    

                

                

                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL549.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 2771.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
医学的免責事項

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.